Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer

BACKGROUND: Treatment options for patients with refractory colorectal cancer are limited and typically provide a chance of only modest benefit. The goal of this study was to evaluate the benefit of inhibiting the JAK/STAT inflammatory pathway with single agent pacritinib in patients with metastatic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Gastrointest Oncol
Asıl Yazarlar: Regenbogen, Thomas, Chen, Ling, Trinkaus, Kathryn, Wang-Gillam, Andrea, Tan, Benjamin R., Amin, Manik, Pedersen, Katrina S., Park, Haeseong, Suresh, Rama, Lim, Kian-Huat, Ratchford, Emily, Brown, Amberly, Lockhart, A. Craig
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5750170/
https://ncbi.nlm.nih.gov/pubmed/29299358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2017.08.16
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller